EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting glutamatergic pathways: genetic insights into comorbid neurodevelopmental disorders

Joseph T Glessner, Munir E Khan, Xiao Chang, Yichuan Liu, Shahram Torkamandi, Deborah Abrams, F George Otieno, Jihoon Kim, Yeshwanth Mahesh, Maria Lemma, Frank Mentch, Jin Li und 5 weitere

Brain · 07.05.2026

DOI: 10.1093/brain/awag152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 07.05.2026. Verfasst von Joseph T Glessner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Applied Genomics, Children's Hospital of Philadelphia Research Institute, Philadelphia PA 19104, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CHOP, NHGRI, Aevi Genomic Medicine Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Copy number variants (CNVs) in genes encoding metabotropic glutamate receptors (GRMs) have been previously implicated in attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). However, investigations of their role in comorbid ADHD patients suffering from coexisting neurodevelopmental disorders (NDDs), such as anxiety and ASD with or without developmental delay remains limited. To assess the enrichment of CNVs in GRM genes and their molecular interaction networks in a large paediatric cohort with ADHD and comorbid NDDs, we analysed CNV data from 72 626 paediatric participants recruited through the Center for Applied Genomics at Children’s Hospital of Philadelphia. The cohort includes 12 472 individuals diagnosed with ADHD (including 7967 with other NDD comorbid conditions). CNVs were identified using PennCNV and annotated for overlap with GRM genes and their protein–protein interaction (PPI) networks using data from Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). We evaluated CNV enrichment in ADHD cases with and without comorbid diagnoses, including autism spectrum disorder (ASD), anxiety and developmental delay. Significant enrichment of CNVs was observed in GRM-interacting networks among ADHD cases with comorbid NDDs. Specifically, 27 genes interacting with primary GRM genes were significantly enriched in CNVs in these individuals with false discovery rate (FDR) < 0.05, compared with ADHD-only cases or disease-free controls. These included key neurodevelopmental genes such as DLG2, NRXN1, SHANK3 and SYNGAP1, which are involved in synaptic signalling and glutamatergic neurotransmission. In contrast, enrichment of GRM network gene CNVs observed in ADHD-only cases was notably less. Our findings support a distinct genetic profile in ADHD cases with comorbid NDDs, marked by CNV enrichment in glutamatergic signalling pathways involving GRM-interacting genes. These results suggest that GRM network disruptions contribute to the complexity of the phenotype spectrum in ADHD patients suffering from comorbid neurodevelopmental phenotypes and highlight a potential pathway for targeted, genetically informed interventions in these patients.

Schlagwörter

Stichwörter der Autor:innen

attention deficit hyperactivity disorderco-morbiditycopy number variationgeneticsneurodevelopmental disorders

Autor:innen und Institutionen

  • Center for Applied Genomics, Children's Hospital of Philadelphia Research Institute, Philadelphia PA 19104, USA.
  • Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA 19104, USA.
  • Department of Cell Biology, the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
  • Divisions on Human Genetics and Pulmonary Medicine, The Children´s Hospital of Philadelphia, Philadelphia PA 19104, USA.

Förderung

  • CHOP
  • NHGRI
  • Aevi Genomic Medicine Inc.
  • Intellectual and Developmental Disabilities Research Center
  • NICHD

Zitieren

APA

Glessner, J. T., Khan, M. E., Chang, X., Liu, Y., Torkamandi, S., Abrams, D., Otieno, F. G., Kim, J., Mahesh, Y., Lemma, M., Mentch, F., Li, J., Kao, C., March, M. E., Qu, H., Connolly, J., & Hakonarson, H. (2026). Targeting glutamatergic pathways: genetic insights into comorbid neurodevelopmental disorders. Brain. https://doi.org/10.1093/brain/awag152

Vancouver

Glessner JT, Khan ME, Chang X, Liu Y, Torkamandi S, Abrams D, et al. Targeting glutamatergic pathways: genetic insights into comorbid neurodevelopmental disorders. Brain. 2026. doi:10.1093/brain/awag152

BibTeX
@article{Glessner2026,
  author = {Glessner, Joseph T and Khan, Munir E and Chang, Xiao and Liu, Yichuan and Torkamandi, Shahram and Abrams, Deborah and Otieno, F George and Kim, Jihoon and Mahesh, Yeshwanth and Lemma, Maria and Mentch, Frank and Li, Jin and Kao, Charlly and March, Michael E and Qu, Huiqi and Connolly, John and Hakonarson, Hakon},
  title = {Targeting glutamatergic pathways: genetic insights into comorbid neurodevelopmental disorders},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag152}
}
Kostenlos starten →